



1642  
SPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Patent Examining Operations

Applicant(s): Ramakrishna et al  
Serial No: 10/006,177 Art Unit: 1642  
Filed: 4 December 2001 Examiner: Yu, Misook  
Title: CYTOTOXIC T-LYMPHOCYTE-INDUCING IMMUNOGENS FOR  
PREVENTION, TREATMENT, AND DIAGNOSIS OF CANCER  
Docket No: 329755-3

22 October 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL**

Sir:

In response to the Office Action, dated 29 September 2004, Applicant submits the following:

1. Response to Restriction Requirement (2 sheets); and
2. Self-addressed, Postage-paid, Return Postcard.

The Commissioner is authorized to charge payment of any fees required in filing this paper or credit any overpayment to Deposit Account No. 03-0678.

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

*Alan J. Grant* 10/22/04  
Alan J. Grant, Esq. Date

Respectfully submitted,

*Alan J. Grant*

Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Patent Examining Operations**

Applicant(s): Ramakrishna et al  
Serial No: 10/006,177 Art Unit: 1642  
Filed: 4 December 2001 Examiner: Yu, Misook  
Title: CYTOTOXIC T-LYMPHOCYTE-INDUCING IMMUNOGENS FOR  
PREVENTION, TREATMENT, AND DIAGNOSIS OF CANCER  
Docket No: 329755-3

22 October 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY TO RESTRICTION REQUIREMENT**

Sir:

In response to the Restriction Requirement, dated 29 September 2004, Applicant elects the invention of Group 4 (claims 1-9, 15), drawn to an immunogen and vaccine composition with traverse.

In addition, Applicants elect SEQ ID NO: 4 for examination. Because the immunogen claims were apparently divided into 20 groups, Applicants believe that SEQ ID NO: 4 is being considered as Group 4.

Applicants believe that the method claims already depend from the composition claims elected for examination and no further amendment of the method claims is required.

The Commissioner is authorized to charge payment of any fees required in filing this paper or credit any overpayment to Deposit Account No. 03-0678.

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

Alan J. Grant

10/22/04

Date

Respectfully submitted,



Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744